AI stocks plunge. Inflation heats up. Where we’re still finding opportunities
The sinking AI trade and hotter-than-expected inflation data rattled last week’s stock market. But solid bank earnings and…
Eli Lilly obesity drug with amylin, tirzepatide boosts weight loss in trial
Eli Lilly on Wednesday said its experimental combination regimen resulted in greater weight loss than a high dose…
Novo’s Wegovy pill improves weight loss after switch from injections
People who switched from obesity injections to Novo‘s new Wegovy pill continued to lose weight after three months,…
Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just…
Novo Nordisk CEO on rebuilding investor trust after backlash
Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in…
Eli Lilly CEO David Ricks discusses GLP-1s and Medicare coverage
Eli Lilly CEO Dave Ricks told CNBC on Monday that 700,000 new seniors have started GLP-1 treatments since…
Lilly is ramping up future manufacturing for Foundayo obesity pill
Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking…
Novo Nordisk rebrands to ‘Novo’ under CEO Mike Doustdar
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in…
This medical device stock looks like a gift for patient investors
Insulet is a high-quality compounder where a temporary execution issue is masking strong underlying fundamentals. Type 2 diabetes…
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.…
Wall Street analysts just called this healthcare stock a buy — here’s our take
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET.…
Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its…